Search Results - "Harb, Diala"

  • Showing 1 - 19 results of 19
Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions by Marleau, Sylvie, Harb, Diala, Bujold, Kim, Avallone, Roberta, Iken, Khadija, Wang, Yanfei, Demers, Annie, Sirois, Martin G, Febbraio, Maria, Silverstein, Roy L, Tremblay, André, Ong, Huy

    Published in The FASEB journal (01-11-2005)
    “…ABSTRACTCD36, a type B scavenger receptor expressed on macrophages, appears to play a major role in fatty streak formation through scavenging oxidatively…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Effect of pancreatic enzyme replacement therapy (PERT) on body weight in advanced pancreatic cancer (APC) by Picozzi, Vincent J., Najjar, Anas, Harb, Diala E, Kort, Jens J, Mandelson, Meg T.

    Published in Journal of clinical oncology (01-02-2023)
    “…698 Background: Malnutrition/cachexia is common in PC and is associated with multiple adverse patient (pt) outcomes. Current NCCN guidelines recommend PERT in…”
    Get full text
    Journal Article
  8. 8

    Real-World Patient Experience With Pancreatic Enzyme Replacement Therapy in the Treatment of Exocrine Pancreatic Insufficiency by Barkin, Jodie A, Harb, Diala, Kort, Jens, Barkin, Jamie S

    Published in Pancreas (01-01-2024)
    “…This study aimed to provide patients insights on the management of exocrine pancreatic insufficiency (EPI) with pancreatic enzyme replacement therapy (PERT). A…”
    Get more information
    Journal Article
  9. 9

    Combination of Ibrutinib with CD19 Chimeric Antigen Receptor (CAR) T Cells Suggests Greater Contribution to CAR T-Cell Efficacy Than Other Approved BTK Inhibitors in the Preclinical Setting by Plaks, Vicki, Cyril, Vidusha, Riedell, Peter A, Zhao, Qianqian, Hall, Jason, Tan, Joel, Harb, Diala, Davids, Matthew S

    Published in Blood (02-11-2023)
    “…Background:CD19-directed CAR T-cell therapy has demonstrated remarkable clinical benefits for patients with B-cell malignancies, but impaired CAR T-cell…”
    Get full text
    Journal Article
  10. 10

    Impact of pancreatic enzyme replacement therapy (PERT) on clinical outcomes in nonresected pancreatic cancer (PC): Initial results by Picozzi, Vincent J., Hawari, Raneem, Najjar, Anas, Harb, Diala E, Kort, Jens J, Mandelson, Margaret T.

    Published in Journal of clinical oncology (20-01-2021)
    “…Abstract only 400 Background: Current NCCN guidelines recommend PERT use in PC patients (pts) with symptoms of EPI. However, little evidence exists regarding…”
    Get full text
    Journal Article
  11. 11

    Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician by Othman, Mohamed O, Harb, Diala, Barkin, Jodie A

    “…In exocrine pancreatic insufficiency (EPI), the quantity and/or activity of pancreatic digestive enzymes are below the levels required for normal digestion,…”
    Get more information
    Journal Article
  12. 12
  13. 13
  14. 14

    Economic Impact of Pancreatic Enzyme Replacement Therapy (PERT) in Pancreatic Cancer Patients Who May Have Exocrine Pancreatic Insufficiency (EPI) Following Pancreatic Surgery by Khandelwal, Nikhil, Harb, Diala, Manthena, Shivaji, Reilly, Patrick, Vora, Jamie, Morris-Stiff, Gareth

    Published in The American journal of gastroenterology (01-10-2018)
    “…Introduction: Exocrine pancreatic insufficiency (EPI) is a known consequence of pancreatic head resection. Following surgery, patients with EPI should be…”
    Get full text
    Journal Article
  15. 15

    Targeting CD36 With EP 80317 Reduces Remote Inflammatory Response to Hind Limb Ischemia‐Reperfusion in Mice by Elimam, Hanan, Gauvin, Jade, Huynh, David N., Ménard, Liliane, Al‐Hawat, Marie‐Lynn, Harb, Diala, Lubell, William D., Carpentier, André C., Ong, Huy, Marleau, Sylvie

    “…Reperfusion of ischemic skeletal muscle triggers oxidative stress and an immediate inflammatory reaction, leading to damage of distant organs such as the…”
    Get full text
    Journal Article
  16. 16

    Factors Influencing Prostate‐Specific Antigen Response among Men Treated with Testosterone Therapy for 6 Months by Morgentaler, Abraham, Benesh, Janet A., Denes, Bela S., Kan‐Dobrosky, Natalia, Harb, Diala, Miller, Michael G.

    Published in Journal of sexual medicine (01-11-2014)
    “…Factors influencing prostate‐specific antigen (PSA) changes in men undergoing testosterone (T) therapy have not been well studied. The aim of this study was to…”
    Get full text
    Journal Article
  17. 17

    The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation by Harb, Diala, Bujold, Kim, Febbraio, Maria, Sirois, Martin G., Ong, Huy, Marleau, Sylvie

    Published in Cardiovascular research (01-07-2009)
    “…Aims CD36 has been shown to associate with non-receptor Src kinases to activate mitogen-activated protein kinases and trigger cytoskeletal remodelling,…”
    Get full text
    Journal Article
  18. 18
  19. 19

    EP80317, a selective ligand of the CD36 scavenger receptor, reduces 111In‐labeled macrophages trafficking to atherosclerotic lesions in apoE‐deficient mice by Harb, Diala, Febbraio, Maria, Ong, Huy, Marleau, Sylvie

    Published in The FASEB journal (01-03-2006)
    “…Our recent studies have shown that long‐term (12 weeks) treatment with growth hormone‐releasing peptides (GHRPs), as ligands of the CD36 scavenger receptor,…”
    Get full text
    Journal Article